Ocular Surgery News U.S. Edition Current Issue
The following articles appeared in the print edition of Ocular Surgery News U.S. Edition.
Table of Contents
- Biosimilars have yet to make an impact in ophthalmology Alex Young
-
- 4D-150 reduces annualized anti-VEGF injection rate in wet AMD at 24 weeks Alex Young
- Corneal tissue addition keratoplasty offers another option for keratoconus treatment Peter S. Hersh, MD, FACS
- FDA clears Faros anterior cataract surgery system
- Luxturna shows long-term maintenance of ambulatory vision, visual field Anthony DeFino
- VIDEO: Good phase 2 results reported for gene therapy in wet AMD at 26 weeks Laurent Fischer, MD; Anthony DeFino
- VIDEO: Port delivery system maintains improvements in diabetic retinopathy at 2 years Margaret Chang, MD, MS; Anthony DeFino
- Do you expect to use more biosimilars in the future? Alex Young
- Careful phaco planning can reduce preexisting astigmatism, improve visual outcome Uday Devgan, MD
-
- Is it time to shift from drops to interventional glaucoma? Kenneth A. Beckman, MD, FACS; I. Paul Singh; Nathan M. Radcliffe, MD
- Middle-aged woman presents with 2 weeks of blurry vision Julia Ernst, MD, PhD; Amal Alwreikat, MD
- Adoption of ophthalmic biosimilars expected to remain slow Richard L. Lindstrom, MD
- Summer breezes: Thoughts while I sits and thinks Darrell E. White, MD